# A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

> **NCT04571385** · PHASE2 · COMPLETED · sponsor: **Acesion Pharma** · enrollment: 66 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** AP30663
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04571385
- **Lead sponsor:** Acesion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2022-12-13
- **Final completion:** 2023-01-23
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571385, "A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04571385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*